Small Molecules

18 Apr 2017 Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
18 Apr 2017 Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
18 Apr 2017 NLS Pharma Announces Completion of Phase 2 Study for NLS-1, Its Lead ADHD Compound; New Investors, New Patents
18 Apr 2017 Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
18 Apr 2017 Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study
17 Apr 2017 Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
14 Apr 2017 Icon Bioscience Submits NDA for DEXYCU, a Potential Transformational Drug Therapy for Treating Inflammation Associated with Cataract Surgery
14 Apr 2017 U.S. FDA Issues Complete Response Letter for Baricitinib
14 Apr 2017 Funding From Alzheimer’s Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials
13 Apr 2017 Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)
13 Apr 2017 FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain Cancer
12 Apr 2017 Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
12 Apr 2017 Regen BioPharma, Inc. Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6
12 Apr 2017 Kadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients
12 Apr 2017 BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
12 Apr 2017 Saniona AB: Saniona's partner, Medix, obtains approval to initiate Phase 3 study in obesity
12 Apr 2017 Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
11 Apr 2017 Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
11 Apr 2017 ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
10 Apr 2017 Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
10 Apr 2017 Ovid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome
10 Apr 2017 Chugai's Alecensa® Met Its Primary Endpoint in the ALEX Study
08 Apr 2017 U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection
07 Apr 2017 Termination of ATM-3507 preclinical development program
07 Apr 2017 Medivir Announces Positive Data From the Phase II Study of Remetinostat in Patients With Early-stage Cutaneous T-cell Lymphoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing